Table of Content

1. China Antibodies Market Scenario
1.1 China Cancer Antibodies Market Sales & Trends Insight
1.2 China Cancer Antibodies Market Future Outlook


2. China Multispecific Cancer Antibodies Market Trends Insight
2.1 China Cancer Bispecific Antibodies Market Scenario
2.2 China Cancer Trispecific Antibodies Market
2.3 China Cancer Tetraspecific Antibodies Market


3. China Lung Cancer Antibodies Market Overview
3.1 Current Market Outlook
3.2 Regulatory Milestones
3.3 Licensing Deals, Collaborations & Clinical Co-Development


4. China Gastric Cancer Antibodies Market Overview
4.1 Current Market Outlook
4.2 Regulatory Milestones
4.3 Licensing Deals, Collaborations & Clinical Co-Development


5. China Breast Cancer Antibodies Market Overview
5.1 Current Market Outlook
5.2 Regulatory Milestones
5.3 Licensing Deals, Collaborations & Clinical Co-Development


6. China Esophagus Cancer Antibodies Market Overview
6.1 Current Market Outlook
6.2 Regulatory Milestones
6.3 Licensing Deals, Collaborations & Clinical Co-Development


7. China Other Cancers Antibodies Market Overview
7.1 Current Market Outlook
7.1.1 Colorectal Cancer
7.1.2 Nasopharyngeal Cancer
7.1.3 Hepatocellular Carcinoma
7.1.4 Ovarian Cancer
7.1.5 Cervical Cancer
7.1.6 Urothelial Cancer
7.1.7 Lymphoma
7.2 Regulatory Milestones
7.3 Licensing Deals, Collaborations & Clinical Co-Development


8. China Cancer Antibodies Clinical Trials Overview
8.1 By Antibody Class (Monoclonal, Bispecific, Trispecific)
8.2 By Drugs Available For Licensing
8.3 By Indication
8.4 By Organization
8.5 By Phase
8.6 By Stage/Therapy Segment


9. China Cancer Antibodies Clinical Trials By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Preregistration
9.9 Registered


10. China Marketed Cancer Antibodies Clinical Insight


11. China Pharmaceutical Sector Regulatory Affairs & Policies Outline
11.1 Approval & Regulatory Bodies
11.2 Government Policy Framework


12. Provisions for Drug Registration: Order of the State Administration for Market Regulation


13. Competitive Landscape
13.1 3SBio
13.2 AD Pharmaceuticals
13.3 Adagene
13.4 Adept Biopharma
13.5 Adlai Nortye
13.6 Akeso Biopharma
13.7 Alphamab Oncology
13.8 Amgen-Beta Pharmaceuticals
13.9 AMPSOURCE Biopharma
13.10 Anhui Anke Biotechnology
13.11 Antengene Corporation
13.12 Ascentage Pharma
13.13 Asieris Pharmaceuticals
13.14 AstraZeneca
13.15 BeiGene
13.16 Beijing Biocytogen
13.17 Beijing Eastern Biotech
13.18 Beijing Eirene Biotech
13.19 Beijing Mabworks Biotech
13.20 Betta Pharmaceuticals Co Ltd
13.21 Bio-Thera Solutions
13.22 BioGene Pharmaceutical
13.23 BioNova Pharmaceuticals
13.24 Biosion
13.25 Biotech Pharmaceutical
13.26 Biotheus
13.27 BJ Bioscience
13.28 Bliss Biopharmaceutical
13.29 BrightGene Bio-medical technology
13.30 Cancer Therapeutics Laboratories
13.31 Dragonboat Biopharmaceutical
13.32 Duality Biologics
13.33 Gmax Biopharm
13.34 Guangzhou Gloria Biosciences
13.35 Hangzhou DAC Biotech
13.36 Hangzhou Rongu Biotechnology
13.37 Hangzhou Sumgen Biotech
13.38 HUTCHMED
13.39 I-MAB Biopharma
13.40 Immvira Pharma
13.41 InnoCare Pharma
13.42 Innovent Biologics
13.43 InxMed
13.44 Jacobio Pharmaceuticals
13.45 Jiangsu Hengrui Medicine Co.
13.46 RemeGen
13.47 Shandong Boan Biotechnology
13.48 Shanghai Henlius Biotech
13.49 Sinocelltech
13.50 Zhejiang Shimai Pharmaceutical



List of Figures

Figure 1-1: China – Cancer Drug Market Opportunity (US$ Billion), 2023 -2028
Figure 1-2: China – Cancer Antibodies Market Opportunity (US$ Billion), 2023 -2028
Figure 1-3: China – Cancer Antibodies Market By Indication (%), 2023
Figure 1-4: Factors Determining the Future of China Antibodies Market

Figure 3-1: China – Toripalimab Annual Sales (US$ Million), 2019 – 2022
Figure 3-2: China – Tislelizumab Quarterly Sales (US$ Million), Q1 – Q4, 2022
Figure 3-3: China – Camrelizumab Negotiation Price (US$) Before & After For 200mg/vial
Figure 3-4: China – Penpulimab Annual Sales (US$ Million), 2021 - 2022

Figure 4-1: China – Tislelizumab Annual Sales (US$ Million), 2020 – 2022
Figure 4-2: China – HANQUYOU Annual Sales (US$ Million), 2020 – 2022

Figure 6-1: China – Tislelizumab Quarterly Sales Comparison (US$ Million), 2021 – 2022

Figure 7-1: China – Elunate Annual Sales (US$ Million), 2020 – 2022
Figure 7-2: China – Cadonilimab Recorded Sales (US$ Million) Since Approval, 2022
Figure 7-3: China – HANLIKANG Annual Sales (US$ Million), 2021 – 2022

Figure 8-1: China – Cancer Antibodies Clinical Trials By Indication, 2023
Figure 8-2: China – Cancer Antibodies In Clinical Trials Available For Licensing, 2023
Figure 8-3: China – Cancer Antibodies Clinical Trials By Indication, 2023
Figure 8-4: China – Cancer Antibodies Clinical Trials By Organization, 2023
Figure 8-5: China – Cancer Antibodies Clinical Trials By Phase, 2023
Figure 8-6: China – Cancer Antibodies Clinical Trials By Therapy Segment, 2023

Figure 11-1: China - Drug Regulatory Framework
Figure 11-2: NMPA - Affiliated Organizations